Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Double homeobox A pseudogene 5 (DUXAP5) is a long non-coding RNA classified as a pseudogene. Although it does not code for a protein, DUXAP5 transcripts play regulatory roles in gene expression and chromatin structure, often via the competing endogenous RNA mechanism, influencing the activity of tumor suppressors and promoters. DUXAP5 has been implicated in several cancers, where its overexpression correlates with tumorigenicity by modulating epigenetic profiles and gene regulatory networks. It is not considered a receptor, enzyme, or conventional therapeutic target, but its expression levels may have clinical utility as a biomarker. No direct evidence supports DUXAP5 as a classic drug target or as having interacting drugs, mechanisms of action, or safety concerns consistent with those of established therapeutic targets. Its main significance is as a non-coding RNA regulator in cancer biology.
Not applicable. DUXAP5 itself is not known to be a direct target for approved drugs, so mechanisms of action are restricted to its molecular roles in ceRNA networks and epigenetic modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double homeobox A pseudogene 5 (DUXAP5).